Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Dividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lemaitre Vascular (LMAT) Amortization of Deferred Charges (2024 - 2026)

Lemaitre Vascular (LMAT) reported Amortization of Deferred Charges of $222000.0 for Q1 2026, up 4.72% year-over-year from $212000.0 in Q1 2025, and up 0.91% on a QoQ basis from $220000.0 in Q4 2025.

Lemaitre Vascular (LMAT) has 3 years of Amortization of Deferred Charges data on file, last reported at $222000.0 in Q1 2026.

  • Quarterly Amortization of Deferred Charges rose 4.72% year-over-year to $222000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $716000.0 (changed N/A YoY) and the FY2025 annual result came in at $873000.0, up 1308.06% from the prior year.
  • Amortization of Deferred Charges advanced to $222000.0 in Q1 2026 per LMAT's latest filing, from $220000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $222000.0 in Q1 2026 and bottomed at $62000.0 in Q4 2024.
  • The 3-year median for Amortization of Deferred Charges is $216000.0 (2025), against an average of $179000.0.
  • The widest annual swing landed in 2025, when Amortization of Deferred Charges surged 254.84%; it then gained 4.72% in 2026.
  • Tracing LMAT's Amortization of Deferred Charges over 3 years: stood at $62000.0 in 2024, then surged by 254.84% to $220000.0 in 2025, then grew by 0.91% to $222000.0 in 2026.
  • Per Business Quant, the three latest LMAT Amortization of Deferred Charges figures stand at $222000.0 (Q1 2026), $220000.0 (Q4 2025), and $212000.0 (Q1 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Intuitive Surgical 156.17 Bn 151.78 Bn 1.83 Bn
2 Becton Dickinson 41.51 Bn 40.49 Bn 2.15 Bn
3 Resmed 30.43 Bn 28.77 Bn 890.98 Mn
4 West Pharmaceutical Services 22.78 Bn 22.26 Bn 296.40 Mn
5 Solventum 13.39 Bn 13.39 Bn 1.10 Bn
6 Cooper Companies 12.33 Bn 12.20 Bn 695.20 Mn
7 Align Technology 11.65 Bn 10.59 Bn 736.59 Mn
8 Baxter International 9.81 Bn 7.77 Bn 891.00 Mn
9 Aptargroup 7.39 Bn 7.19 Bn 351.91 Mn
10 Lemaitre Vascular 2.28 Bn 1.91 Bn 48.40 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 222,000.00
Mar 31, 2026 222,000.00
Dec 31, 2025 220,000.00
Dec 31, 2025 220,000.00
Mar 31, 2025 212,000.00
Mar 31, 2025 212,000.00
Dec 31, 2024 62,000.00
Dec 31, 2024 62,000.00